News

GLP-1 agonists for weight loss increased the risk of pancreatitis, gastroparesis, and bowel obstruction compared with the use of bupropion-naltrexone.

This announcement by Arcutis broadens the psoriasis drug’s indication and was done to help simplify management of the skin condition for younger patients as well.

Compared to placebo, patients using once-daily oral HU6 100 mg, HU6 300 mg, and HU6 450 mg experienced significant changes in liver fat, volume, and whole-body adiposity after 61 days of treatment.

This new data may help clinicians not to over-treat or over-medicalize with infants that have a SARS-CoV-2 infection.

An interview regarding the current impacts of environmental health on food availability, nutrition, and more.

An institution's review of prescriptions in the first year since dupilumab's historic FDA approval for eosinopihlic esophagitis shows patients waited a mean 46 days to initiate the biologic therapy.

Stephen Greene, MD, discusses trials, data, and themes to look for at the HFSA 2023 meeting.

The latest episode of our mini-docuseries focuses on disparities in ophthalmology, from preventable vision impairment to gaps in access in underserved communities.

A new study seeks to compare the outcomes of biopsies among American children at risk of celiac disease, with European thresholds that would deem such biopsies unnecessary.

Findings from the pivotal phase 3 trial that which supported linaclotide's FDA approval show significant benefit in bowel movement and stool consistency.

Our ophthalmology month in review for September 2023 highlights our top stories in retina, the latest news from the FDA, and insights into the evolving specialty landscape.

The author of the largest clinical trial for pediatric PFIC to date discusses the various benefit maralixibat provides to disease managementr.

A new review and analysis suggests a combination treatment regimen for children in acute liver failure due to autoimmune hepatitis may help them maintain native liver survival.

Pooled phase 3 data presented at NASPGHAN 2023 support the benefit-risk profile of the IBAT inhibtor in treating the rare liver disease.

Results demonstrated comparable safety, immunogenicity, and pharmacokinetics between adalimumab-afzb and the reference product.

Annualized costs for the 24-month study period were highest among patients with both NASH and T2D, highlighting the incremental cost of adding an additional diagnosis for comorbid NASH or T2D.

Parents in the active disease group indicated greater levels of anxiety than parents of children without active IBD, suggesting a correlation between parental mental health and their child’s disease activity.

The rheumatology month in review highlights top data from the 2023 CCR West, CBT for reducing pain catastrophizing in patients with fibromyalgia, and the link between gout and a reduced likelihood of Alzheimer Disease.

This new synthetic data set could work as a potential resource for training on AI as well as to help facilitate a consensus among clinicians.

This installment in our Unprevented series examines the growing impact of chronic kidney disease on public health and what those in the field are doing to mitigate this growing crisis.

A new initiative from the HFSA highlights key findings on heart failure prevalence, risk, mortality and hospitalization rates in the United States.

The biosimilar month in review highlights an interview with leading experts, the latest data regarding switching between biologics and biosimilars, and the efficacy of infliximab biosimilars among patients with inflammatory conditions.

Phase 1/2 trial data shows all patients with T1D treated with VX-880 achieved improved glycemic control and a reduction or elimination of external insulin needs.

Amid the escalating threat of wildfires due to climate change, the medical and public health communities face an increasing responsibility to develop robust emergency response plans to safeguard patients and healthcare infrastructure.

In a new study, 50% of adolescents admitted into a psychiatric hospital screened positive for insomnia.

Patients aged less than 45 years at NAFLD onset had a higher risk of cancer compared to older age groups, highlighting an association between younger age at NAFLD onset and cancer risk.

Our endocrinology month in review for September 2023 spotlights news related to semaglutide and a pair of articles offering a deep dive into comorbidities in type 1 and type 2 diabetes.

Nondiabetic and diabetic patients without retinopathy experience similar results after treatment with an intravitreal dexamethasone implant for pseudophakic macular edema.